Table 3 Estimated risk of death or chronic disability per 1 million population resulting from L. loa encephalopathy following mass treatment with Mectizan^®, under conditions of: 1) no mass treatment; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy. Four scenarios are considered based on high and low prevalence of loiasis and onchocerciasis, respectively (defined in the Appendix - see additional file 1).

From: A Framework for Decision-Making for Mass Distribution of Mectizan^® in Areas Endemic for Loa loa